Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome

Velidi H. Rao, Daniel T. Meehan, Duane Delimont, Motowo Nakajima, Takashi Wada, Michael Ann Gratton, Dominic E Cosgrove

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Alport syndrome is a glomerular basement membrane (GBM) disease caused by mutations in type IV collagen genes. A unique irregular thickening and thinning of the GBM characterizes the progressive glomerular pathology. The metabolic imbalances responsible for these GBM irregularities are not known. Here we show that macrophage metalloelastase (MMP-12) expression is >40-fold induced in glomeruli from Alport mice and is markedly induced in glomeruli of both humans and dogs with Alport syndrome. Treatment of Alport mice with MMI270 (CGS27023A), a broad spectrum MMP inhibitor that blocks MMP-12 activity, results in largely restored GBM ultrastructure and function. Treatment with BAY-129566, a broad spectrum MMP inhibitor that does not inhibit MMP-12, had no effect. We show that inhibition of CC chemokine receptor 2 (CCR2) receptor signaling with propagermanium blocks induction of MMP-12 mRNA and prevents GBM damage. CCR2 receptor is expressed in glomerular podocytes of Alport mice, suggesting MCP-1 activation of CCR2 on podocytes may underlie induction of MMP-12. These data indicate that the irregular GBM that characterizes Alport syndrome may be mediated, in part, by focal degradation of the GBM due to MMP dysregulation, in particular, MMP-12. Thus, MMP-12/CCR2 inhibitors may provide a novel and effective therapeutic strategy for Alport glomerular disease.

Original languageEnglish (US)
Pages (from-to)32-46
Number of pages15
JournalAmerican Journal of Pathology
Volume169
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Matrix Metalloproteinase 12
Hereditary Nephritis
Glomerular Basement Membrane
Matrix Metalloproteinases
CCR2 Receptors
Podocytes
Matrix Metalloproteinase Inhibitors
Collagen Type IV
Dogs
Pathology
Messenger RNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome. / Rao, Velidi H.; Meehan, Daniel T.; Delimont, Duane; Nakajima, Motowo; Wada, Takashi; Gratton, Michael Ann; Cosgrove, Dominic E.

In: American Journal of Pathology, Vol. 169, No. 1, 01.01.2006, p. 32-46.

Research output: Contribution to journalArticle

Rao, Velidi H. ; Meehan, Daniel T. ; Delimont, Duane ; Nakajima, Motowo ; Wada, Takashi ; Gratton, Michael Ann ; Cosgrove, Dominic E. / Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome. In: American Journal of Pathology. 2006 ; Vol. 169, No. 1. pp. 32-46.
@article{18af609e437d4cce8f736c685e9e58b0,
title = "Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome",
abstract = "Alport syndrome is a glomerular basement membrane (GBM) disease caused by mutations in type IV collagen genes. A unique irregular thickening and thinning of the GBM characterizes the progressive glomerular pathology. The metabolic imbalances responsible for these GBM irregularities are not known. Here we show that macrophage metalloelastase (MMP-12) expression is >40-fold induced in glomeruli from Alport mice and is markedly induced in glomeruli of both humans and dogs with Alport syndrome. Treatment of Alport mice with MMI270 (CGS27023A), a broad spectrum MMP inhibitor that blocks MMP-12 activity, results in largely restored GBM ultrastructure and function. Treatment with BAY-129566, a broad spectrum MMP inhibitor that does not inhibit MMP-12, had no effect. We show that inhibition of CC chemokine receptor 2 (CCR2) receptor signaling with propagermanium blocks induction of MMP-12 mRNA and prevents GBM damage. CCR2 receptor is expressed in glomerular podocytes of Alport mice, suggesting MCP-1 activation of CCR2 on podocytes may underlie induction of MMP-12. These data indicate that the irregular GBM that characterizes Alport syndrome may be mediated, in part, by focal degradation of the GBM due to MMP dysregulation, in particular, MMP-12. Thus, MMP-12/CCR2 inhibitors may provide a novel and effective therapeutic strategy for Alport glomerular disease.",
author = "Rao, {Velidi H.} and Meehan, {Daniel T.} and Duane Delimont and Motowo Nakajima and Takashi Wada and Gratton, {Michael Ann} and Cosgrove, {Dominic E}",
year = "2006",
month = "1",
day = "1",
doi = "10.2353/ajpath.2006.050896",
language = "English (US)",
volume = "169",
pages = "32--46",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome

AU - Rao, Velidi H.

AU - Meehan, Daniel T.

AU - Delimont, Duane

AU - Nakajima, Motowo

AU - Wada, Takashi

AU - Gratton, Michael Ann

AU - Cosgrove, Dominic E

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Alport syndrome is a glomerular basement membrane (GBM) disease caused by mutations in type IV collagen genes. A unique irregular thickening and thinning of the GBM characterizes the progressive glomerular pathology. The metabolic imbalances responsible for these GBM irregularities are not known. Here we show that macrophage metalloelastase (MMP-12) expression is >40-fold induced in glomeruli from Alport mice and is markedly induced in glomeruli of both humans and dogs with Alport syndrome. Treatment of Alport mice with MMI270 (CGS27023A), a broad spectrum MMP inhibitor that blocks MMP-12 activity, results in largely restored GBM ultrastructure and function. Treatment with BAY-129566, a broad spectrum MMP inhibitor that does not inhibit MMP-12, had no effect. We show that inhibition of CC chemokine receptor 2 (CCR2) receptor signaling with propagermanium blocks induction of MMP-12 mRNA and prevents GBM damage. CCR2 receptor is expressed in glomerular podocytes of Alport mice, suggesting MCP-1 activation of CCR2 on podocytes may underlie induction of MMP-12. These data indicate that the irregular GBM that characterizes Alport syndrome may be mediated, in part, by focal degradation of the GBM due to MMP dysregulation, in particular, MMP-12. Thus, MMP-12/CCR2 inhibitors may provide a novel and effective therapeutic strategy for Alport glomerular disease.

AB - Alport syndrome is a glomerular basement membrane (GBM) disease caused by mutations in type IV collagen genes. A unique irregular thickening and thinning of the GBM characterizes the progressive glomerular pathology. The metabolic imbalances responsible for these GBM irregularities are not known. Here we show that macrophage metalloelastase (MMP-12) expression is >40-fold induced in glomeruli from Alport mice and is markedly induced in glomeruli of both humans and dogs with Alport syndrome. Treatment of Alport mice with MMI270 (CGS27023A), a broad spectrum MMP inhibitor that blocks MMP-12 activity, results in largely restored GBM ultrastructure and function. Treatment with BAY-129566, a broad spectrum MMP inhibitor that does not inhibit MMP-12, had no effect. We show that inhibition of CC chemokine receptor 2 (CCR2) receptor signaling with propagermanium blocks induction of MMP-12 mRNA and prevents GBM damage. CCR2 receptor is expressed in glomerular podocytes of Alport mice, suggesting MCP-1 activation of CCR2 on podocytes may underlie induction of MMP-12. These data indicate that the irregular GBM that characterizes Alport syndrome may be mediated, in part, by focal degradation of the GBM due to MMP dysregulation, in particular, MMP-12. Thus, MMP-12/CCR2 inhibitors may provide a novel and effective therapeutic strategy for Alport glomerular disease.

UR - http://www.scopus.com/inward/record.url?scp=33745686157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745686157&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2006.050896

DO - 10.2353/ajpath.2006.050896

M3 - Article

VL - 169

SP - 32

EP - 46

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 1

ER -